Having trouble accessing articles? Reset your cache.

Carfilzomib: Phase IIb data

Top-line data from the open-label, North American pivotal Phase IIb PX-171-003-A1 trial in 266 patients showed that IV carfilzomib produced an ORR of 24%, with a median duration of

Read the full 294 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE